#USA #financial results #BioLife Solutions #Bothell #cell processing

BioLife Solutions Reports Third Quarter 2025 Financial Results

BioLife Solutions, Inc. (Nasdaq: BLFS), a key player in the cell and gene therapy market, has announced its financial performance for the third quarter of 2025. Despite the challenges faced in the biotechnology sector, the company has shown significant growth, especially in its cell processing revenue which rose by 33% compared to Q3 2024, reaching $25.4 million.

Financial Highlights

As released on November 6, 2025, BioLife's total revenue for Q3 2025 was $28.1 million, marking a 31% increase from $21.4 million in the same quarter last year. This growth is largely attributed to the rising demand for biopreservation media and related products within the biopharmaceutical market. To illustrate, the cell processing revenue represented a substantial portion of this total, underscoring the company's strong foothold in critical therapeutic areas.

In terms of overall performance, the company is projecting its full-year guidance to grow considerably, with total revenues now expected to range between $95 million and $96 million. This is adjusted due to recent shifts within the company's portfolio, particularly the strategic divestiture of its evo cold chain logistics subsidiary.

Significant Achievements

One of the key takeaways from BioLife's latest report is that its biopreservation media is currently being used in roughly 250 clinical trials across the United States, representing a market share of more than 70%. Notably, this includes over 30 Phase III trials, which are crucial for the advancement of therapeutic drugs. Furthermore, the company's tools, including CellSeal vials and hPL products, play a vital role in over 35 clinical trials.

Operational Metrics

Operationally, BioLife achieved a GAAP net income of $0.6 million, a remarkable turnaround from a net loss of $0.5 million in the previous year. The adjusted EBITDA reached $7.8 million, accounting for 28% of revenue, highlighting operational efficiency and cost management.

Despite a slight dip in gross margins, with GAAP gross margin recorded at 62% compared to 63% in Q3 2024, the company is adeptly navigating inventory challenges while maintaining profitability. The adjusted gross margin also followed a similar trend at 64%. On the flip side, operating losses decreased from $0.4 million in Q3 2024 to $0.1 million in the latest quarter, signaling continuous improvement in operational performance.

Looking Ahead

Roderick de Greef, BioLife's Chairman and CEO, expressed optimism about the future. He emphasized that the divestiture of the evo cold chain logistics business has refined BioLife's focus, positioning it as a leading player in the cell processing niche. He stated, “By aligning the organization around our core cell processing business, we are driving sustainable, high-quality growth.”

The firm anticipates significant operational momentum with the expected approval of additional commercial CGTs (cell and gene therapies) in the next year. In fact, ten new product approvals and geographic expansions are anticipated within 12 months, reinforcing BioLife's role in advancing innovative therapies.

Financial Stability

By the close of Q3 2025, BioLife reported a solid cash position with cash, cash equivalents, and marketable securities amounting to $98.4 million. This financial stability bodes well for continued investments in research and development, as well as potential strategic partnerships.

In conclusion, BioLife Solutions stands on robust pillars of growth and innovation as it navigates the complexities of the biotechnology landscape. With a clear focus and strategic direction, the company is well-equipped to achieve its ambitious goals moving forward into the future.